View Older Stories View More Recent Stories

Dec 12, 2022 07:00AM Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
Dec 12, 2022 07:00AM Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
Dec 1, 2022 07:01AM Orchard Therapeutics (ORTX) Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy
Dec 1, 2022 07:00AM Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
Dec 1, 2022 07:00AM Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
Nov 14, 2022 07:00AM Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
Nov 14, 2022 07:00AM Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
Nov 8, 2022 07:00AM Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022
Nov 8, 2022 07:00AM Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022
Nov 7, 2022 07:00AM Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results
Nov 7, 2022 07:00AM Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results
Nov 3, 2022 09:05AM Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
Nov 3, 2022 09:05AM Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
Oct 12, 2022 11:12AM SCORE - MENTORS TO AMERICA'S SMALL BUSINESSES - WELCOMES NEW BOARD MEMBERS
Oct 10, 2022 07:00AM Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
Oct 10, 2022 07:00AM Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
Aug 29, 2022 07:00AM Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
Aug 29, 2022 07:00AM Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
Aug 4, 2022 07:00AM Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
Aug 4, 2022 07:00AM Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
May 12, 2022 07:00AM Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
May 10, 2022 07:00AM Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
May 10, 2022 07:00AM Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
May 5, 2022 07:00AM Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
May 5, 2022 07:00AM Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
May 2, 2022 07:00AM Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany
May 2, 2022 07:00AM Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany
Apr 11, 2022 07:00AM Orchard Therapeutics Plc (ORTX) Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
Apr 11, 2022 07:00AM Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
Apr 11, 2022 07:00AM Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
Mar 30, 2022 07:00AM Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
Mar 30, 2022 07:00AM Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
Mar 24, 2022 07:00AM Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results
Mar 24, 2022 07:00AM Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results
Mar 3, 2022 07:00AM Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022
Mar 3, 2022 07:00AM Orchard Therapeutics to Present at Multiple Investor Conferences in March 2022
Feb 24, 2022 04:05PM Cryoport Reports Fourth Quarter and Full Year 2021 Results
Feb 7, 2022 07:00AM Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
Feb 7, 2022 07:00AM Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
Feb 3, 2022 07:01PM Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients
Feb 3, 2022 07:01PM Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients
Jan 21, 2022 07:00AM Orchard Therapeutics (ORTX) Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
Jan 21, 2022 07:00AM Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
Jan 21, 2022 07:00AM Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
Jan 10, 2022 07:00AM Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
Jan 10, 2022 07:00AM Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
Jan 4, 2022 07:00AM Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Jan 4, 2022 07:00AM Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 10, 2021 08:00PM Annual Changes to the Nasdaq Biotechnology Index
Nov 18, 2021 07:17AM Orchard Therapeutics (ORTX) Announces NEJM Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
View More Recent Stories View Older Stories